论文部分内容阅读
Gefitinib is the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),which is often prescribed for non-small-cell lung cancer therapy with serious adverse effects on gastrointestinal physiology, such as nausea, vomiting, diarrhea and emaciation.